The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Martin J. Edelman

University of Maryland Greenebaum Cancer Center

Baltimore

USA

[email]@umm.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of Maryland Greenebaum Cancer Center, Baltimore, USA. 2001 - 2012
  • Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. 2012
  • Division of Medical Oncology, University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA. 2008
  • Cancer Center, University of California Davis, Davis, California, USA. 2001

References

  1. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. Edelman, M.J., Harb, W.A., Pal, S.E., Boccia, R.V., Kraut, M.J., Bonomi, P., Conley, B.A., Rogers, J.S., Messmann, R.A., Garon, E.B. J. Thorac. Oncol (2012) [Pubmed]
  2. Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view. Edelman, M.J., Le Chevalier, T., Soria, J.C. J. Thorac. Oncol (2012) [Pubmed]
  3. Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non-Small-Cell Lung Cancer. Edelman, M.J., Hodgson, L., Wang, X., Kratzke, R.A., Vokes, E.E. J. Clin. Oncol. (2012) [Pubmed]
  4. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Edelman, M.J., Belani, C.P., Socinski, M.A., Ansari, R.H., Obasaju, C.K., Chen, R., Monberg, M.J., Treat, J. J. Thorac. Oncol (2010) [Pubmed]
  5. Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. Edelman, M.J., Burrows, W., Krasna, M.J., Bedor, M., Smith, R., Suntharalingam, M. Lung. Cancer (2010) [Pubmed]
  6. Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog. Edelman, M.J., Clamon, G., Kahn, D., Magram, M., Lister-James, J., Line, B.R. J. Thorac. Oncol (2009) [Pubmed]
  7. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Edelman, M.J. Clin. Lung. Cancer (2009) [Pubmed]
  8. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Edelman, M.J., Suntharalingam, M., Burrows, W., Kwong, K.F., Mitra, N., Gamliel, Z., Riley, M., Cooper, L.B., Kennedy, N.L., Buskirk, S., Hausner, P., Doyle, L.A., Krasna, M.J. Ann. Thorac. Surg. (2008) [Pubmed]
  9. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. Edelman, M.J., Watson, D., Wang, X., Morrison, C., Kratzke, R.A., Jewell, S., Hodgson, L., Mauer, A.M., Gajra, A., Masters, G.A., Bedor, M., Vokes, E.E., Green, M.J. J. Clin. Oncol. (2008) [Pubmed]
  10. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Edelman, M.J., Bauer, K.S., Wu, S., Smith, R., Bisacia, S., Dancey, J. Clin. Cancer Res. (2007) [Pubmed]
  11. Novel cytotoxic agents for non-small cell lung cancer. Edelman, M.J. J. Thorac. Oncol (2006) [Pubmed]
  12. Geographic variation in the second-line treatment of non-small cell lung cancer. Edelman, M.J., Sekine, I., Tamura, T., Saijo, N. Semin. Oncol. (2006) [Pubmed]
  13. Lung cancer - Second Annual Winter Conference. Edelman, M.J. IDrugs (2005) [Pubmed]
  14. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. Edelman, M.J., Smith, R., Hausner, P., Doyle, L.A., Kalra, K., Kendall, J., Bedor, M., Bisaccia, S. J. Clin. Oncol. (2005) [Pubmed]
  15. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Edelman, M.J. Clin. Lung. Cancer (2005) [Pubmed]
  16. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer. Edelman, M.J. Semin. Oncol. (2005) [Pubmed]
  17. Evidence-based approaches to overcoming barriers to clinical trial accrual. Edelman, M.J. Cancer. J (2004) [Pubmed]
  18. Second-line chemotherapy and beyond for non-small-cell lung cancer. Edelman, M.J. Clin. Adv. Hematol. Oncol (2004) [Pubmed]
  19. The management of the patient undergoing combined modality therapy for locally advanced non-small cell lung cancer. Edelman, M.J., Suntharalingam, M., Krasna, M.J. Curr. Treat. Options. Oncol (2003) [Pubmed]
  20. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Edelman, M.J., Bauer, K., Khanwani, S., Tait, N., Trepel, J., Karp, J., Nemieboka, N., Chung, E.J., Van Echo, D. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  21. Treatment options for brain metastases in patients with non-small-cell lung cancer. Taimur, S., Edelman, M.J. Curr. Oncol. Rep (2003) [Pubmed]
  22. Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials. Edelman, M.J. Clin. Lung. Cancer (2003) [Pubmed]
  23. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection. Edelman, M.J., Schuetz, J. Curr. Treat. Options. Oncol (2002) [Pubmed]
  24. Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer. Edelman, M.J. Lung. Cancer (2002) [Pubmed]
  25. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Edelman, M.J., Gandara, D.R., Lau, D.H., Lara, P., Lauder, I.J., Tracy, D. Cancer (2001) [Pubmed]
  26. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Edelman, M.J., Quam, H., Mullins, B. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  27. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. Edelman, M.J. Expert. Rev. Anticancer. Ther (2001) [Pubmed]
 
WikiGenes - Universities